制药

Apotex's EUR74m sale of subsidiaries to Aurobindo

Apotex on the sale of six European subsidiaries in Belgium, Poland, the Netherlands, Czech Republic and Spain, to Aurobindo for EUR74 million. This highly complex transaction involved the share transfer of subsidiaries in multiple jurisdictions being co-ordinated and managed by our UK team. We simultaneously advised on a multitude of business separation, ongoing product supply agreements and IP licences for the European business to continue operating after being removed from the Apotex group.

Pharmaceutical portfolio divestments across 24 EU jurisdictions

Teva Pharmaceuticals Europe BV on its divestments of portfolios of generic pharmaceutical products (approximately 260 medicinal products) in 24 EU jurisdictions to multiple purchasers, in addition to advising Teva on the divestment of certain parts of its business. The divestments were a condition enforced by the European Commission to approve Teva's USD40.5 billion acquisition of Allergan plc’s global generics and have been run as a competitive auction process, resulting in five asset sales.

HKD1.3 billion takeover on CITIC 21CN by Alibaba Group

CITIC 21CN Co., Limited (HKEX: 0241) (now known as Alibaba Health Information Technology Limited), a member of CITIC Group (HKEX: 0267), on a HKD1.3 billion takeover by Alibaba Group (NYSE: BABA; HKEX: 9988) (one of China's largest e-commerce companies) and Yunfeng Capital (the venture capital firm set up by Alibaba Group founder, Jack Ma). Alibaba and Yunfeng obtained a whitewash waiver and took a controlling stake without triggering a mandatory general offer.